Acute Conjunctivitis Treatment Market Expected to Reach US$ 563.9 Mn by 2025
Posted by Shristi on October 21st, 2019
“The Global Acute Conjunctivitis Treatment Market growing at a significant CAGR over seven years forecast period 2019-2025 to reach US$ 563.9 Mn by 2025 owing to grow in incidence of conjunctivitis.”
Precision Business Insights (PBI) in its report titled “Global Acute Conjunctivitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
The global acute conjunctivitis treatment market was valued at US$ XX Mn in 2018 and increasing at a significant CAGR over the forecast timeframe owing to surge in incidence of conjunctivitis around the globe. For instance, according to a research study, approximately 2% of people are affected with acute conjunctivitis every year around the world. Moreover, rise in R&D for the development and launch of newer therapeutics, government initiatives to prevent the ophthalmic diseases, and advanced healthcare services in developed and developing countries are expected to drive the global acute conjunctivitis treatment market. However, limited number of branded drugs, stringent regulations for the product approval, and patent expiry of blockbuster drugs are anticipated to hinder the revenue share of global acute conjunctivitis treatment market.
Global acute conjunctivitis treatment market segmented on the basis of drug class, disease type, dosage form, distribution channel, and region
Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=16241
Antihistamines Segment Dominates the Global Acute Conjunctivitis Treatment Market
Based on the drug class, global acute conjunctivitis treatment market segmented into antihistamines, antibiotics, mast cell stabilizers, anti-inflammatory drugs, and others. Mast cell stabilizers dominated the global acute conjunctivitis treatment market in 2018 and estimated to dominate over the forecast period owing to innovation of newer therapeutics by the companies, rise in awareness about the acute conjunctivitis treatment among the people, and launch of generics into market. However, a slow growth rate observed for the antihistamine drugs due to low cost of products and entry of generics into the market.
North America Leads the Global Acute Conjunctivitis Treatment Market
PBI’s global acute conjunctivitis treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to increase in the prevalence of acute conjunctivitis, rise in awareness about the ophthalmic diseases, and rise in healthcare expenditure are propel the market. Asia Pacific acute conjunctivitis treatment market anticipated to exhibit substantial growth over the forthcoming years due to entry of market players into developing countries such as India and China and advanced healthcare infrastructure in the region.
Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players
Global acute conjunctivitis treatment market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region.
For instance, in June 2017, Teva Pharmaceuticals launched generic version of Pataday (olopatadine hydrochloride ophthalmic solution) 0.2% for the treatment of acute conjunctivitis.
Key player’s profiles in the report are Novartis AG, Pfizer Inc., Sanofi S.A., Allergan plc, Boehringer Ingelheim GmbH, Bausch & Lomb Inc., CIBA Vision Ophthalmics, Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd.
By Drug Class
By Disease Type
By Dosage Form
By Distribution Channel
Middle East and Africa (MEA)
Like it? Share it!
About the AuthorShristi
Joined: September 17th, 2019
Articles Posted: 60
More by this author